The face of healthcare delivery is transforming, with a significant shift towards patient-centered care (PCC). This approach prioritizes the patient's needs, values, and preferences, fostering a partnership between clinicians and patients to improve health outcomes.
PCC is a healthcare delivery model that focuses on the patient's unique needs. It promotes active involvement of patients in their healthcare decisions, encouraging them to be informed and empowered. PCC aims to enhance patient satisfaction, improve health outcomes, and reduce healthcare costs.
Effective PCC models incorporate several key elements. These include respect for patients' values and preferences, coordination and integration of care, information and education, physical comfort, emotional support, involvement of family and friends, and transition and continuity.
PCC has been associated with numerous benefits. It can lead to improved patient satisfaction, better health outcomes, decreased healthcare utilization, and reduced costs. PCC also plays a crucial role in enhancing healthcare quality by promoting patient safety, effectiveness, efficiency, and equitability.
Despite its benefits, implementing PCC can be challenging. Barriers include resistance to change, lack of resources, and difficulty in measuring patient-centered outcomes. However, these challenges can be overcome by fostering a culture of patient-centeredness, providing adequate resources and training, and developing robust methods to measure and improve PCC.
As healthcare continues to evolve, PCC models are becoming increasingly important. By prioritizing the needs and preferences of patients, these models have the potential to transform healthcare delivery, leading to improved patient satisfaction, better health outcomes, and reduced costs. Therefore, embracing PCC is not merely a trend, but a necessary shift in the healthcare paradigm.
1.
A new way to measure suicide risk?
2.
3D virtual staining technology enables non-invasive observation of cancer tissue
3.
Perioperative Nivolumab Boosts EFS Versus Neoadjuvant-Only Nivolumab in NSCLC
4.
I Understand Why Defense Secretary Austin Kept His Prostate Cancer Quiet.
5.
ASCO: Vepdegestrant ups survival in ER+, HER2− advanced breast cancer with ESR1 mutations
1.
Hemophilia B and Gene Therapy: A New Chapter with Etranacogene Dezaparvovec
2.
Driving Impact: Oncology Pharmaceutical Marketing Strategies in the USA
3.
7 Subtle Signs of Leukemia: How to Spot the Symptoms Early
4.
Predicting Incidental Prostate Cancer in BPH Surgery Patients
5.
How Should We Approach Solid Pseudopapillary Neoplasm of the Pancreas with Hepatic Metastases?
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part V
2.
The Comprehensive Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2.
3.
Current Scenario of Cancer- Q&A Session to Close the Gap Part II
4.
Unmet Needs in ALK Positive NSCLC- The Challenges in the Current Care
5.
Navigating the Complexities of Ph Negative ALL - Part IX
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation